What are the ingredients in vevye eye drops?

What are the active ingredients in Vevye eye drops?
Vevye contains 0.1 % cyclosporine, the only active ingredient listed on the product label. The formulation is a water-free solution designed to increase corneal penetration of cyclosporine.

How does the inactive-ingredient list differ from Restasis?
Vevye’s vehicle is perfluorobutylpentane with ethanol as a solubilizer; Restasis uses castor oil and polysorbate 80. The absence of oils and surfactants in Vevye reduces blur and burning reported by some Restasis users.

When does the patent on Vevye expire?
The composition-of-matter patent (U.S. 10,076,504) expires in November 2033, with potential pediatric exclusivity extending protection into 2034. DrugPatentWatch.com tracks the full family and any Paragraph IV challenges.

Can a generic version of Vevye reach the market before 2033?
No abbreviated new drug application has been filed yet. Because Vevye is protected by both formulation and method-of-use patents, any generic would need to demonstrate bioequivalence in a dry-eye indication and navigate ongoing litigation risk.

What side effects are patients most likely to report?
The most common adverse reactions in clinical trials were instillation-site pain (8 %) and reduced visual acuity (3 %). These events were generally mild and resolved without discontinuation.

Who manufactures Vevye and where is it available?
Harrow Health produces Vevye in the United States; the product launched in early 2023 and is dispensed through most major retail and specialty pharmacies.